Enesi Pharma secures Innovate UK Funding to enable scalable aseptic manufacturing of ImplaVax®-enabled solid dose viral vector vaccines.
Enesi Pharma, the innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, is delighted to announce that it has secured substantial funding from Innovate UK, the UK's innovation agency, under the Biomedical Catalyst 2019 Round 1: Early and Late Stage Awards Initiative.
The award of £870,419 will co-fund a major new £1.24 million project to develop a scalable aseptic manufacturing process for live or live-attenuated viral vectors for use with Enesi's ImplaVax® needle-free solid dose technology.
See the full details here
to our newsletter delivered every second week not to miss important reimbursement information.